CIK 0001677077
- Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811822909
- Phone
- +1 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Open-market buy 10% owner bought 2,300 shares at $0.91 ($2,082)
- 4 Open-market buy 10% owner bought 10,000 shares at $0.98 ($9,773)
- 4 Open-market buy 10% owner bought 10,000 shares at $0.88 ($8,830)
- 4 Open-market buy 10% owner bought 10,000 shares at $0.88 ($8,841)
- 4 Open-market buy 10% owner bought 10,000 shares at $0.87 ($8,740)
- 4 Open-market buy 10% owner bought 10,000 shares at $0.85 ($8,474)
- 4 Open-market buy 10% owner bought 8,000 shares at $0.95 ($7,576)
- 4 Open-market buy 10% owner bought 2,000 shares at $0.94 ($1,881)
- 4 Open-market buy 10% owner bought 8,000 shares at $0.96 ($7,679)
- 4 Open-market buy 10% owner bought 22,000 shares at an average $0.94 ($20,627)
- 4 Open-market buy 10% owner bought 16,100 shares at $0.89 ($14,306)
- 4 Other acquisition 10% owner acquired 3,900 shares (other)
- 4 Open-market buy 10% owner bought 23,900 shares at $0.98 ($23,343)
- 4 Open-market buy 10% owner bought 125,000 shares at an average $0.97 ($121,298)
- 4 Open-market buy 10% owner bought 100,000 shares at $1.07 ($106,850)
- 4 Open-market buy 10% owner bought 2,666,667 shares at $1.50 ($4,000,001)
- 4 Option exercise Director acquired 250,000 shares (option exercise)
- 4 Open-market buy 10% owner bought 75,000 shares at $0.94 ($70,335)
- 4 Open-market buy 10% owner bought 50,000 shares at $1.13 ($56,325)
- 4/A Open-market sale Director sold 25,000 shares at $1.21 ($30,325)
Page 5 of 9 · 170 filings